Sep 14, 2021

Success 14.09.2021 The acquisition of Metys broadens Novaremed’s pipeline focused on novel, non-opioid development candidates for chronic pain indications with the addition of two complementary development projects. Among them is the patented Phase 2 clinical candidate MP-101. Novaremed , a privately-held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG (Metys), including all of its development programs, in an all-share transaction. The acquisition broadens Novaremed’s existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment, the company’s focus area. From now on, Novaremed’s pipeline to address neuropathic pain will focus on three non-opioid development projects with entirely different modes of action. The company’s candidate NDR NRD.E1, an orally active small molecule with a novel mechanism of action and patent protection until 2040. It acts as a Lyn kinase modulator and is the lead compound being developed to treat painful diabetic peripheral neuropathy (PDPN), affecting 1 in five diabetic patients. With positive results from Phase 2a dose-finding proof-of-concept study, an FDA Fast Track Designation and IND-approval Novaremed is ready to proceed with a 12-week Phase 2b study in patients with moderate to severe PDPN in the US. The newly acquired candidate MP-101, a Phase 2 clinical candidate, is an orally available modulator of glutamate signaling. It works by preventing or reversing the ramped-up signaling that occurs in the spine and brain due to damaged peripheral nerves. MP-101 is a patented non-racemic mixture of dimiracetam enantiomers with patent protection until 2039. Based on positive results from Phase 1 and Phase 2 clinical studies, MP-101 is being developed to manage chemotherapy-induced neuropathy and neuropathic pain. The Phase 2 trial is expected to start in the first quarter of 2023. Another candidate, MP-103, a glutamate signaling modulator orally active in diverse rodent models for preventing and treating peripheral nerve injury symptoms, is set to start Phase 1 clinical development in the first half of 2023.